Healthcare Revenue Cycle · Healthcare & Life Sciences
Should you build or buy AI Prior Authorization Automation?
AI Prior Authorization Automation software streamlines the prior authorization process for clinical services and medications — submitting PA requests to payers electronically, tracking authorization status in real time, predicting approval likelihood using clinical AI, and flagging cases likely to require peer-to-peer review before service delivery.
The build-vs-buy decision for AI Prior Authorization Automation turns on how much of the value is real-time payer API connectivity that only vendors have assembled at scale versus clinical AI accuracy that depends on training data from diverse payer contracts, and how quickly the CMS FHIR mandate is standardizing the connectivity infrastructure that has historically been the vendor moat.
Build it, buy it, or bridge?
When building makes sense
The build case for prior authorization automation is real but premature for most organizations in 2026. The CMS prior authorization mandate is standardizing payer APIs through FHIR, which means the connectivity layer that has historically been the vendor moat will gradually become a commodity. As payers publish standardized FHIR endpoints, building payer connectivity becomes a software problem rather than a business development problem. The remaining vendor value will concentrate in clinical AI accuracy — how well the model predicts PA outcomes and flags likely denials before submission. That accuracy depends on training data from diverse payer contracts at scale. Individual health systems can't yet accumulate that training corpus, but as FHIR adoption deepens, the calculus shifts meaningfully. The build case looks different in 2028 than it does today. Organizations evaluating this should track FHIR endpoint availability by payer rather than committing to a long-term vendor contract on the current connectivity model.
When buying makes sense
Buying AI prior authorization automation makes sense for most health systems and provider groups today because the vendor's core value is payer connectivity that has taken years to assemble. Each payer has its own criteria, forms, and API behavior, and covering a meaningful portion of a health system's payer mix requires direct technical relationships with hundreds of individual payers. Vendors like Cohere Health and Waystar have built those connections, and no provider organization starting from scratch today can replicate that coverage on a reasonable timeline. Buying is also the practical answer because clinical AI accuracy for PA decisions depends on training data from diverse payer contracts — the volume of labeled PA outcomes that vendors accumulate across customers is not replicable at the individual system level. The decision calculus is worth revisiting as FHIR payer API adoption matures, but in 2026 vendor connectivity coverage dominates the economics.
The desk read
Prior authorization automation lives and dies on payer connectivity. Each payer has its own criteria, forms, and API behavior, and covering a meaningful portion of a health system's payer mix requires direct technical relationships with hundreds of individual payers. Vendors like Cohere Health and Waystar have built those connections over years, and a provider organization starting from scratch today couldn't replicate that coverage in any reasonable timeframe.
The CMS prior authorization mandate is beginning to standardize the API layer through FHIR, which will gradually shift the build calculus. As payers publish standardized endpoints, the connectivity moat erodes and the remaining vendor value concentrates in clinical AI accuracy: how well the model predicts PA outcomes and flags denials before submission. That accuracy depends on training data from diverse payer contracts at scale, which individual health systems still can't accumulate on their own. The decision sits differently in 2026 than it will in 2028 as FHIR adoption deepens.
Frequently asked
What is AI Prior Authorization Automation software?
AI Prior Authorization Automation software streamlines the prior authorization process for clinical services and medications — submitting PA requests to payers electronically, tracking authorization status in real time, predicting approval likelihood using clinical AI, and flagging cases likely to require peer-to-peer review before service delivery.
When does building AI Prior Authorization Automation make sense?
Building isn't yet viable for most organizations in 2026 because real-time payer connectivity requires direct technical relationships with hundreds of payers that individual health systems can't replicate. The calculus will shift as FHIR payer API adoption deepens and standardizes the connectivity layer — tracking that adoption is more useful than committing to a long-term vendor contract today.
When does buying AI Prior Authorization Automation make sense?
Buying makes sense for most health systems and provider groups today — vendor payer connectivity and clinical AI models trained on diverse cross-payer data are not independently replicable. Both reduce denial rates and physician satisfaction friction in ways that justify the platform cost.
What are the main AI Prior Authorization Automation vendors?
Representative vendors include Cohere Health, Myndshft (DrFirst), Waystar Auth Accelerate, CoverMyMeds (McKesson). B4 Pro scores the full set.